PFS
Figure 1 · Panel A
Panel A 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Xichun Hu, Qingyuan Zhang, Tao Sun, Yongmei Yin, Huiping Li, Min Yan, Zhongsheng Tong, Man Li, Yue'e Teng, Christina Pimentel Oppermann, Govind Babu Kanakasetty, Ma Coccia Portugal, Liu Yang, Wanli Zhang, Zefei Jiang
Chin Med J (Engl) 138(12) 1477-1486
BACKGROUND: In the interim analysis of MONARCH plus, adding abemaciclib to endocrine therapy (ET) improved progression-free survival (PFS) and objective response rate (ORR) in predominantly Chinese postmenopausal women with HR+/HER2- advanced breast cancer (ABC). This study presents the final pre-planned PFS analysis. METHODS: In the phase III MONARCH plus study, postmenopausal women in China, India, Brazil, and South Africa with HR+/HER2- ABC without prior systemic therapy in an advanced setting (cohort A) or progression on prior ET (cohort B) were randomized (2:1) to abemaciclib (150 mg twice daily [BID]) or placebo plus: anastrozole (1.0 mg/day) or letrozole (2.5 mg/day) (cohort A) or fulvestrant (500 mg on days 1 and 15 of cycle 1 and then on day 1 of each subsequent cycle) (cohort B). The primary endpoint was PFS of cohort A. Secondary endpoints included cohort B PFS (key secondary endpoint), ORR, overall survival (OS), safety, and health-related quality of life (HRQoL). RESULTS: In cohort A (abemaciclib: n = 207; placebo: n = 99), abemaciclib plus a non-steroidal aromatase inhibitor improved median PFS vs . placebo (28.27 months vs . 14.73 months, hazard ratio [HR]: 0.476; 95% confidence interval [95% CI]: 0.348-0.649). In cohort B (abemaciclib: n = 104; placebo: n = 53), abemaciclib plus fulvestrant improved median PFS vs . placebo (11.41 months vs . 5.59 months, HR: 0.480; 95% CI: 0.322-0.715). Abemaciclib numerically improved ORR. Although immature, a trend toward OS benefit with abemaciclib was observed (cohort A: HR: 0.893, 95% CI: 0.553-1.443; cohort B: HR: 0.512, 95% CI: 0.281-0.931). The most frequent grade ≥3 adverse events in the abemaciclib arms were neutropenia, leukopenia, anemia (both cohorts), and lymphocytopenia (cohort B). Abemaciclib did not cause clinically meaningful changes in patient-reported global health, functioning, or most symptoms vs . placebo. CONCLUSIONS: Abemaciclib plus ET led to improvements in PFS and ORR, a manageable safety profile, and sustained HRQoL, providing clinical benefit without a high toxicity burden or reduced quality of life. TRIAL REGISTRATION: ClinicalTrials.gov (NCT02763566).
2 个 Figure · 4 个 KM 面板
Figure 1 Kaplan–Meier plot of PFS in the ITT population in (A) cohort A and (B) cohort B. * HR stratified by nature of disease and prior ET; † Log-rank stratified nominal P value (two-sided) for comparison of treatment vs. placebo + NSAI; ‡ HR stratified by nature of disease, sensitivity to ET; § Log-rank stratified nominal P -value (two-sided) for comparison of treatment vs. placebo + fulvestrant. CI: Confidence interval; ET: Endocrine therapy; HR: Hazard ratio; ITT: Intention-to-treat; NSAI: Non-steroidal aromatase inhibitor; PFS: Progression-free survival.
Figure 1 · Panel A
Panel A 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 1 · Panel B
Panel B 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 4 Kaplan–Meier plots of TTD in mBPI-SF worst pain with increased analgesic use in (A) cohort A and (B) cohort B. TTD in pain was estimated using combined data from mBPI-SF and analgesic use, where deterioration in pain was defined as an increase of ≥2 points in mBPI-SF “worst pain” score from baseline (previously established as the minimally important difference), [26] or an increase of ≥1 level of analgesic drug class from baseline. † HR, stratified HR from Cox proportional hazard model and 95% CI by nature of disease; ‡ Log-rank stratified nominal P value (two-sided) for comparison of treatment vs. placebo + NSAI; § HR – stratified HR from Cox proportional hazard model and 95% CI by nature of disease; ¶ Log-rank stratified nominal P value (two-sided) for comparison of treatment vs . placebo + fulvestrant. 95% CI: 95% confidence interval; HR: Hazard ratio; mBPI-SF: Modified Brief Pain Inventory-Short Form; NSAI: Non-steroidal aromatase inhibitor; TTD: Time to deterioration; TTSD: Time to sustained deterioration.
Figure 4 · Panel A
Panel A 是同一 Figure 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 4 · Panel B
Panel B 是同一 Figure 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。